Get notified when PHGE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (new) — Management concluded disclosure controls are ineffective as of March 31, 2026, representing a control deficiency.
BiomX pivots to defense tech via acquisitions; flags ineffective controls, delisting risk
Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read
Key Changes
-
high
Management concluded disclosure controls are ineffective as of March 31, 2026, reversing prior year's effective determination. Company plans to consult third-party advisors but provides no timeline or detail on the deficiency.
Controls & Procedures verify on EDGAR → -
high
Company abandoned phage therapy, discontinued lead BX004 program, replaced entire management and board, and acquired two Israeli defense/security tech firms (DFSL laser radar, Zorronet AI security) in Q1 2026.
MD&A: Business Overview verify on EDGAR → -
high
Israeli operating subsidiary BiomX Ltd. entered insolvency in December 2025, was deconsolidated in January 2026, and is no longer controlled by the company or deemed part of its assets.
MD&A: BiomX Israel verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade PHGE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 26, 2026 · How we verify